The application of carbon nanoparticles in D2 gastrectomy and lymph nodes harvesting for locally advanced gastric cancer

Phase III, prospective, multi-center, randomize-controlled study on the application of carbon nanoparticles in D2 gastrectomy and lymph nodes harvesting for locally advanced gastric cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16008244

Enrollment

Unknown

Registered

2016-04-08

Start date

2016-04-10

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Standard:D2 Lymphadenectomy

CNP:CNP Injection+D2 Lymphadenectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Gastric cancer diagnosed by gastroscopy and biopsy; 2) Staging diagnosis is complete by means of enhanced CT scan and/or endoscopic ultrasonography (EUS); 3) Clinical staging is cT2-4 N0-3 M0; 4) ECOG less than 2 points, tolerant for gastrectomy and D2 lymph node dissection; 5) Be able to follow the study instructions and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Remnant gastric cancer, recurrent gastric cancer and abdominopelvic multiple primary cancer; 2) D2 lymph node dissection is not performed; 3) Metastatic gastric cancer is confirmed by intraoperative exploration; 4) Non gastric cancer is confirmed by postoperative pathological examination; 5) The sampling or report of lymph nodes does not conform to the standards in this study.

Design outcomes

Primary

Measure	Time frame
Total number of lymph nodes;	—

Secondary

Measure	Time frame
Total number of stained lymph nodes;	—

Countries

China

Contacts

Public ContactJia-Fu Ji

jiafuj@hotmail.com+8601088196048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026